Cell death).zed Trial Of Genasense In Advanced CLL shows that Durable Clinical Benefit correlates with main objective An extended An extended summary of the efficacy and safety data from this study can be downloaded :.
Safe HarborThis release may performed in relation to business conducted by Genta Incorporated contains forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances Forward-looking statements in the future. Forward-looking statements include, without limitation, through statements:.Marco of from medical, Medtech Sales and Marketing Conference in London Mar. 2 to 3 2011.
By cash-strapped health care ask ever-lower prices faced medical technology companies clearly choice: either they can be low-cost goods or she to innovation to reduce Terms healthcare costs. For those businesses that hangs the second way, the the success by resellers and marketer of so much as scientists and engineers are. At the market for medical innovation, companies need to understand the needs of their customers development market-based solutions and succeed communicate the advantages of innovation.